{
    "clinical_study": {
        "@rank": "38410", 
        "acronym": "METALL", 
        "arm_group": {
            "arm_group_label": "Methylprednisolone 500 mg", 
            "arm_group_type": "Experimental", 
            "description": "Methylprednisolone 500 mg administered intravenously at baseline"
        }, 
        "brief_summary": {
            "textblock": "In this study, efficacy of methylprednisolone in reduction of signs and symptoms (back pain,\n      stiffness, joint pain and swelling) of active ankylosing spondylitis (AS) will be\n      investigated. It is expected, that a single dose of methylprednisolone 500 mg given\n      intravenously at baseline will lead to a rapid reduction of symptoms of active AS, which can\n      be seen already 2 weeks after drug administration."
        }, 
        "brief_title": "Efficacy and Safety of MEthylprednisolone Administered Intravenously for the Treatment of Patients With Active AnkyLosing spondyLitis (METALL)", 
        "condition": "Ankylosing Spondylitis", 
        "condition_browse": {
            "mesh_term": [
                "Spondylitis", 
                "Spondylitis, Ankylosing"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age of \u226518 years.\n\n          -  Definite diagnosis of AS according to the modified New York criteria.\n\n          -  History of an inadequate response to \u22652  nonsteroidal antiinflammatory drugs (NSAIDs)\n             taken for at least 2 weeks each or NSAIDs intolerance.\n\n          -  Active disease as defined by the Bath Ankylosing Spondylitis DIsease Activity Index\n             (BASDAI) value of \u22654 at screening despite concomitant treatment with an NSAID or\n             without NSAIDs in case of intolerance.\n\n        Exclusion Criteria:\n\n          -  The female subject is pregnant or lactating.\n\n          -  Patients with other chronic inflammatory articular disease or systemic autoimmune\n             disease.\n\n          -  History of inadequate response to previous anti-tumour necrosis factor (TNF) \u03b1\n             therapy.\n\n          -  Treatment with any other investigational drug within 4 weeks of 5 half-life of the\n             drug (whichever is longer) prior to baseline.\n\n          -  Treatments with disease modifying anti-rheumatic drugs (DMARDs) other than\n             methotrexate within 4 weeks prior to screening (8 weeks for leflunomide or 4 weeks\n             with a standard cholestyramine wash-out).\n\n          -  Treatment with intravenous, intramuscular or intraarticular/periarticular steroids\n             within 4 weeks prior to screening.\n\n          -  History of oesophageal, gastric, duodenal or intestinal ulceration, clinically\n             relevant gastrointestinal bleeding.\n\n          -  History of or current signs of coronary heart disease, myocardial infarction, stroke\n             or transient ischemic attack, peripheral arterial thrombotic events.\n\n          -  Congestive heart failure (NYHA III-IV)\n\n          -  Uncontrolled arterial hypertension.\n\n          -  History of diabetes mellitus.\n\n          -  History of glaucoma.\n\n          -  Major surgery within 12 weeks prior to screening.\n\n          -  Evidence of any other severe uncontrolled gastrointestinal, hepatic, renal,\n             pulmonary, cardiovascular, nervous or endocrine disorders.\n\n          -  Any active current viral, bacterial or fungal infection, a history of recurrent\n             clinically significant infection, infections requiring treatment with antibiotics\n             within 4 weeks prior to baseline.\n\n          -  History of chronic infection with hepatitis B or C, history of HIV infection.\n\n          -  Primary or secondary immunodeficiency.\n\n          -  Any other conditions making the patient unsuitable in the opinion of the investigator\n             for the participation in the current study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01790022", 
            "org_study_id": "METALL 2012"
        }, 
        "intervention": {
            "arm_group_label": "Methylprednisolone 500 mg", 
            "intervention_name": "Methylprednisolone", 
            "intervention_type": "Drug", 
            "other_name": "Metypred, Medrol, Solu-Medrol"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Methylprednisolone acetate", 
                "Prednisolone acetate", 
                "Methylprednisolone", 
                "Methylprednisolone Hemisuccinate", 
                "Prednisolone", 
                "Prednisolone hemisuccinate", 
                "Prednisolone phosphate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 9, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Saratov", 
                    "country": "Russian Federation"
                }, 
                "name": "Department of Rheumatology, Saratov Region Hospital"
            }
        }, 
        "location_countries": {
            "country": "Russian Federation"
        }, 
        "number_of_arms": "1", 
        "official_title": "Efficacy and Safety of MEthylprednisolone Administered Intravenously for the Treatment of Patients With Active AnkyLosing spondyLitis (METALL) - a 12-week, Prospective, Open-label, Pilot Study", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Russia: Ethics Committee"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The Assessment of Spondyloarthritis International Society 40 (ASAS40) response is defined as an improvement of \u226540% and \u22652 points in at least 3 out of four following domains (and no worsening in remaining domain):\nPatient global\nPain\nFunction (as measured by the Bath Ankylosing Spondylitis Functional Index - BASFI)\nInflammation (mean of the Bath Ankylosing Spondylitis Disease Activity Index - BASDAI question 5 and 6)", 
            "measure": "The Assessment of Spondyloarthritis International Society 40 (ASAS40) response", 
            "safety_issue": "No", 
            "time_frame": "Week 2"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01790022"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Saratov State Medical University", 
            "investigator_full_name": "Denis Poddubnyy", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Saratov State Medical University", 
        "sponsors": {
            "collaborator": {
                "agency": "Charite University, Berlin, Germany", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Saratov State Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}